Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Net Income of -$644.76 million for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$644.76M | -39.1% |
| 2024 | -$463.66M | -41.3% |
| 2023 | -$328.07M | -37.0% |
| 2022 | -$239.48M | -28.4% |
| 2021 | -$186.48M | -114.3% |
| 2020 | -$87.01M | -40.6% |
| 2019 | -$61.88M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$162.25M | -69.3% | +5.6% |
| June 30, 2025 | -$171.90M | -76.2% | +15.1% |
| March 31, 2025 | -$202.49M | -121.6% | -111.3% |
| September 30, 2024 | -$95.84M | -3.0% | +1.7% |
| June 30, 2024 | -$97.54M | -27.1% | -6.7% |
| March 31, 2024 | -$91.37M | -39.9% | +1.8% |
| September 30, 2023 | -$93.02M | -53.9% | -21.2% |
| June 30, 2023 | -$76.73M | -17.0% | -17.4% |
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -39.1% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, RECURSION PHARMACEUTICALS, INC.’s net income has declined by 942.0% (from -$61.88 million to -$644.76 million).
- The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: